L John Doerr Purchases 2,832,440 Shares of Amyris Inc (AMRS) Stock

Amyris Inc (NASDAQ:AMRS) Director L John Doerr purchased 2,832,440 shares of the stock in a transaction on Wednesday, April 24th. The shares were purchased at an average price of $5.12 per share, with a total value of $14,502,092.80. Following the acquisition, the director now directly owns 5,532 shares in the company, valued at $28,323.84. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

L John Doerr also recently made the following trade(s):

  • On Monday, April 15th, L John Doerr purchased 6,732,369 shares of Amyris stock. The shares were purchased at an average price of $2.87 per share, with a total value of $19,321,899.03.

NASDAQ AMRS opened at $4.75 on Monday. Amyris Inc has a 52 week low of $1.87 and a 52 week high of $9.28. The company has a market cap of $363.50 million, a price-to-earnings ratio of -1.88 and a beta of 0.29.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of $0.44 by ($1.51). The firm had revenue of $19.36 million for the quarter, compared to analyst estimates of $98.52 million. The company’s revenue was down 76.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.61 EPS. Equities analysts forecast that Amyris Inc will post -0.31 earnings per share for the current fiscal year.

AMRS has been the subject of several analyst reports. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. HC Wainwright set a $11.00 price target on shares of Amyris and gave the stock a “buy” rating in a report on Tuesday, February 5th. Finally, BidaskClub cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Amyris currently has an average rating of “Buy” and an average price target of $8.83.

Several large investors have recently modified their holdings of AMRS. Wells Fargo & Company MN lifted its position in shares of Amyris by 50.6% during the 3rd quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock worth $333,000 after buying an additional 14,075 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Amyris by 8.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 115,388 shares of the biotechnology company’s stock worth $916,000 after buying an additional 9,172 shares during the last quarter. BlackRock Inc. lifted its position in shares of Amyris by 32.8% during the 3rd quarter. BlackRock Inc. now owns 2,277,432 shares of the biotechnology company’s stock worth $18,082,000 after buying an additional 562,877 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Amyris by 96.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 446,909 shares of the biotechnology company’s stock worth $3,548,000 after buying an additional 219,081 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Amyris by 106.2% during the 3rd quarter. Renaissance Technologies LLC now owns 53,783 shares of the biotechnology company’s stock worth $427,000 after buying an additional 27,700 shares during the last quarter. Institutional investors and hedge funds own 36.69% of the company’s stock.

WARNING: “L John Doerr Purchases 2,832,440 Shares of Amyris Inc (AMRS) Stock” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2019/04/29/l-john-doerr-purchases-2832440-shares-of-amyris-inc-amrs-stock.html.

About Amyris

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Story: What are no-load funds?

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.